SAN DIEGO, Aug 12, 2010 (BUSINESS WIRE) — Cytori Therapeutics (CYTX 4.69, +0.13, +2.88%) has received U.S. Patent No. 7,771,716 (the ‘716 patent) for Celution(R) System based methods of treating musculoskeletal disorders such as spinal disc disease. The ‘716 patent covers the therapeutic use of adipose-derived stem and regenerative cells (ADRCs) for promoting repair and regeneration of the spinal disc and formation of bone, cartilage, skeletal muscle, tendon and ligaments.
“This addition to our patent portfolio significantly expands protection for the therapeutic uses of the Celution(R) System output for orthopedics, one of the largest markets in regenerative medicine,” said Dr. Marc Hedrick, President of Cytori. “Our technology has shown great potential for disc disease, a spectrum of conditions for which current treatments generally attempt to address the symptoms rather than repair the damaged tissue.”
In December 2008, Cytori presented 12 month preclinical results indicating that ADRCs can promote repair of damaged spinal discs. In a large animal model, ADRC-treated discs showed a significant increase in disc tissue density and disc-specific extracellular matrix components.
The ‘716 patent includes 61 dependent claims covering site of cell delivery, additives to the Celution(R) System output, surgical implants, scaffolds, spinal fusion devices for use with the Celution(R) System output, cell culture and differentiation of the Celution(R) System output as well as a variety of disaggregation agents and device configurations. Cytori’s Celution(R) System automates the extraction of the stem and regenerative cells naturally occurring in adipose tissue for both clinical and research use.
The patent builds upon the Company’s patent strategy covering methods of obtaining and processing of stem and regenerative cells from adipose tissue. The ‘716 patent is the 10th U.S. patent issued to the Company, with 14 international patents and more than 100 patent applications pending worldwide relating to devices, methods and uses of adipose-derived stem and regenerative cells.
Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution(R) System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource(R) product line is sold globally for cell banking and research applications. www.cytori.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2009. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.
SOURCE: Cytori Therapeutics